The People's Insurance Company (Group) of China Limited (PINXY)
OTCMKTS
· Delayed Price · Currency is USD
10.19
0.00 (0.00%)
At close: Apr 23, 2025
PINXY Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2015 - 2019 |
---|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2015 - 2019 |
Premiums & Annuity Revenue | 537,709 | 503,900 | 468,802 | 529,891 | 520,581 | Upgrade
|
Total Interest & Dividend Income | 1,533 | 17,086 | 10,713 | 38,708 | 37,318 | Upgrade
|
Gain (Loss) on Sale of Investments | 25,166 | -13,565 | -5,185 | 11,501 | 9,070 | Upgrade
|
Other Revenue | 17,122 | 17,906 | 18,493 | 14,448 | 15,170 | Upgrade
|
Total Revenue | 581,530 | 525,327 | 492,823 | 594,548 | 582,139 | Upgrade
|
Revenue Growth (YoY) | 10.70% | 6.59% | -17.11% | 2.13% | 5.67% | Upgrade
|
Policy Benefits | 500,301 | 479,397 | 439,680 | 423,403 | 382,837 | Upgrade
|
Policy Acquisition & Underwriting Costs | - | - | - | 50,939 | 62,489 | Upgrade
|
Selling, General & Administrative | 9,131 | 9,224 | 7,752 | 90,360 | 107,584 | Upgrade
|
Provision for Bad Debts | -65 | -6 | - | - | - | Upgrade
|
Other Operating Expenses | -397 | -438 | -434 | 1,566 | 1,589 | Upgrade
|
Total Operating Expenses | 509,031 | 488,252 | 447,079 | 566,926 | 555,514 | Upgrade
|
Operating Income | 72,499 | 37,075 | 45,744 | 27,622 | 26,625 | Upgrade
|
Interest Expense | -1,471 | -1,463 | -2,206 | -5,460 | -5,607 | Upgrade
|
Earnings From Equity Investments | - | - | - | 13,571 | 11,413 | Upgrade
|
Currency Exchange Gain (Loss) | 64 | 228 | 1,002 | -331 | -816 | Upgrade
|
Other Non Operating Income (Expenses) | -69 | -60 | -205 | - | - | Upgrade
|
EBT Excluding Unusual Items | 71,023 | 35,780 | 44,335 | 35,402 | 31,615 | Upgrade
|
Gain (Loss) on Sale of Assets | 174 | 209 | 321 | 330 | 128 | Upgrade
|
Asset Writedown | -472 | -463 | -182 | -143 | -133 | Upgrade
|
Other Unusual Items | -1,493 | -1,969 | -1,757 | - | - | Upgrade
|
Pretax Income | 69,232 | 33,557 | 42,717 | 35,589 | 31,610 | Upgrade
|
Income Tax Expense | 12,451 | 2,746 | 7,270 | 5,219 | 3,377 | Upgrade
|
Earnings From Continuing Ops. | 56,781 | 30,811 | 35,447 | 30,370 | 28,233 | Upgrade
|
Minority Interest in Earnings | -14,630 | -8,489 | -10,065 | -8,894 | -8,197 | Upgrade
|
Net Income | 42,151 | 22,322 | 25,382 | 21,476 | 20,036 | Upgrade
|
Net Income to Common | 42,151 | 22,322 | 25,382 | 21,476 | 20,036 | Upgrade
|
Net Income Growth | 88.83% | -12.06% | 18.19% | 7.19% | -9.48% | Upgrade
|
Shares Outstanding (Basic) | 44,224 | 44,224 | 44,224 | 44,224 | 44,224 | Upgrade
|
Shares Outstanding (Diluted) | 44,224 | 44,224 | 44,224 | 44,224 | 44,224 | Upgrade
|
EPS (Basic) | 0.95 | 0.50 | 0.57 | 0.49 | 0.45 | Upgrade
|
EPS (Diluted) | 0.91 | 0.48 | 0.56 | 0.49 | 0.45 | Upgrade
|
EPS Growth | 91.67% | -14.14% | 14.33% | 7.92% | -10.09% | Upgrade
|
Free Cash Flow | 83,593 | 66,976 | 64,545 | 69,076 | 20,251 | Upgrade
|
Free Cash Flow Per Share | 1.89 | 1.51 | 1.46 | 1.56 | 0.46 | Upgrade
|
Dividend Per Share | 0.180 | 0.156 | 0.166 | 0.164 | 0.156 | Upgrade
|
Dividend Growth | 15.38% | -6.02% | 1.22% | 5.13% | 34.48% | Upgrade
|
Operating Margin | 12.47% | 7.06% | 9.28% | 4.65% | 4.57% | Upgrade
|
Profit Margin | 7.25% | 4.25% | 5.15% | 3.61% | 3.44% | Upgrade
|
Free Cash Flow Margin | 14.37% | 12.75% | 13.10% | 11.62% | 3.48% | Upgrade
|
EBITDA | 75,045 | 39,635 | 48,370 | 30,144 | 29,002 | Upgrade
|
EBITDA Margin | 12.90% | 7.54% | 9.81% | 5.07% | 4.98% | Upgrade
|
D&A For EBITDA | 2,546 | 2,560 | 2,626 | 2,522 | 2,377 | Upgrade
|
EBIT | 72,499 | 37,075 | 45,744 | 27,622 | 26,625 | Upgrade
|
EBIT Margin | 12.47% | 7.06% | 9.28% | 4.65% | 4.57% | Upgrade
|
Effective Tax Rate | 17.98% | 8.18% | 17.02% | 14.67% | 10.68% | Upgrade
|
Revenue as Reported | 622,220 | 553,467 | 528,527 | 594,606 | 581,605 | Upgrade
|
Source: S&P Global Market Intelligence. Insurance template. Financial Sources.